Norman David Eansor Form 4 BIO-TECHNE / Norman David Eansor ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Eansor Norman David

(Last) (First) (Middle)

8100 SOUTHPARK WAY, A-8

(Street)

LITTLETON CO 80120

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP - Novus Biologicals

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2019

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2019		S(1)		3,117	D	$215	0.00	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)							(3)	(3)	Common Stock	2,287		2,287	D
Restricted Stock Units	(2)							(4)	(4)	Common Stock	2,174		2,174	D
Restricted Stock Units	(2)							(5)	(5)	Common Stock	2,537		2,537	D
Stock Option (Right to Buy)	$108.49							(6)	08/07/2022	Common Stock	12,500		12,500	D
Stock Option (Right to Buy)	$94.35							(7)	08/12/2021	Common Stock	15,000		15,000	D
Stock Options (Right to buy)	$177.32							(8)	08/08/2025	Common Stock	18,066		18,066	D
Stock Options (Right to buy)	$177.32							(5)	08/08/2025	Common Stock	13,550		13,550	D
Stock Options (Right to buy)	$125.05							(4)	08/09/2024	Common Stock	11,982		11,982	D
Stock Options (Right to buy)	$125.05							(9)	08/09/2024	Common Stock	15,976		15,976	D
Stock Options (Right to buy)	$108.49							(7)	08/07/2022	Common Stock	7,494		7,494	D
Stock Options (Right to buy)	$106.59							(10)	08/18/2023	Common Stock	18,819		18,819	D
Stock Options (Right to buy)	$106.59							(3)	08/18/2023	Common Stock	14,114		14,114	D

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2019.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

3. Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

4. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

5. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

6. 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

7. Fully exercisable

8. Vest 4,517 shares on each 8/8/2019, 8/9/2020 and 4,516 shares on 8/8/2021, 8/9/2022

9. Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021

10. Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Remarks:

	/s/ Brenda S. Furlow, attorney in fact for N. David Eansor pursuant to Power of Attorney previously filed	06/14/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.